Cipla on Sunday announced the closure of the inspection by the US health regulator at the company’s API manufacturing facility in Bengaluru.
“Following the inspection by the United States Food and Drug Administration at the Company’s API manufacturing facility in Virgonagar, Bengaluru, from July 15 to 19, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection,” the company said in a filing to the BSE.
It had earlier said that the USFDA issued seven observations after conducting a routine ‘CGMP inspection’ at the facility.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.